The Centers for Medicare & Medicaid Services today announced a new Section 1115 waiver policy that allows states to design demonstration projects that increase access to treatment for opioid use disorders and other substance use disorders. CMS’s new demonstration policy would allow state Medicaid programs to reimburse for substance abuse treatment provided at inpatient facilities with more than 16 beds otherwise prohibited by the current Institutions for Mental Diseases exclusion. While the new policy will provide states with an expedited review process, it does require that states submit a detailed implementation plan that articulates how they will meet the new policy’s specific goals and milestones to improve OUD and SUD treatment and reduce opioid related deaths. In addition to the implementation plan, states also must comply with periodic reporting and evaluations. CMS also announced approval of New Jersey and Utah’s 1115 demonstration waivers under the new policy.

Related News Articles

Headline
The Department of Health and Human Services this week awarded $487 million in fiscal year 2019 grants to help states and territories increase access to…
Headline
The three medications approved by the Food and Drug Administration to treat opioid use disorder — methadone, buprenorphine and extended-release naltrexone —…
Headline
In a study of Blue Cross and Blue Shield enrollees reported last week in the New England Journal of Medicine, initial opioid prescriptions declined 54 percent…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing on the president’s fiscal year 2020 budget request for the Department of Health and…
Headline
Eligible organizations can apply through May 6 for up to $1 million each for a three-year period to expand opioid and other substance use disorder services in…
Insights and Analysis
Birmingham VA Medical Center’s weekly, 90-minute shared medical appointments help veterans address opioid reliance.